Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of tipifarnib and erlotinib
hydrochloride in treating patients with solid tumors that have spread to other places in the
body. Tipifarnib and erlotinib hydrochloride may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.